BACKGROUND: Prenatal and infant acetaminophen exposure has been associated with an increased risk of childhood asthma phenotypes. Demonstration of biologically plausible interactions between these exposures and maternal and child antioxidant gene polymorphisms would strengthen causal inference. OBJECTIVE: To explore potential interactions between prenatal and infant acetaminophen exposure and antioxidant genotypes on childhood asthma. METHODS: In the Avon Longitudinal Study of Parents and Children, we typed a functional nuclear erythroid 2 p45-related factor 2 (Nrf2) polymorphism and glutathione S-transferase (GST) M1, T1, and P1 polymorphisms. Effects of prenatal and infant acetaminophen exposure on asthma phenotypes at 7 years were stratified by genotype in >4000 mothers and >5000 children. RESULTS: Risk of asthma and wheezing associated with early gestation acetaminophen exposure was increased when maternal copies of the minor T allele of Nrf2 were present (P interactions, .02 and .04, respectively). Risk of asthma associated with late gestation exposure was higher when maternal GSTT1 genotype was present rather than absent (P interaction, .006), and risk of wheezing was increased when maternal GSTM1 was present (P interaction, .04). Although acetaminophen use in infancy was associated with an increased risk of atopy, child antioxidant genotype did not modify associations between infant acetaminophen use and asthma phenotypes. However, the increased risk of asthma and wheezing associated with late gestation acetaminophen exposure in the presence of maternal GSTM1 was further enhanced when GSTM1 was also present in the child. CONCLUSION: Maternal antioxidant gene polymorphisms may modify the relation between prenatal acetaminophen exposure and childhood asthma, strengthening evidence for a causal association. In contrast, relations between infant acetaminophen use and asthma and atopy were not modified by child genotype and may be confounded by pre-existing wheeze or allergy.
BACKGROUND: Prenatal and infant acetaminophen exposure has been associated with an increased risk of childhood asthma phenotypes. Demonstration of biologically plausible interactions between these exposures and maternal and child antioxidant gene polymorphisms would strengthen causal inference. OBJECTIVE: To explore potential interactions between prenatal and infant acetaminophen exposure and antioxidant genotypes on childhood asthma. METHODS: In the Avon Longitudinal Study of Parents and Children, we typed a functional nuclear erythroid 2 p45-related factor 2 (Nrf2) polymorphism and glutathione S-transferase (GST) M1, T1, and P1 polymorphisms. Effects of prenatal and infant acetaminophen exposure on asthma phenotypes at 7 years were stratified by genotype in >4000 mothers and >5000 children. RESULTS: Risk of asthma and wheezing associated with early gestation acetaminophen exposure was increased when maternal copies of the minor T allele of Nrf2 were present (P interactions, .02 and .04, respectively). Risk of asthma associated with late gestation exposure was higher when maternal GSTT1 genotype was present rather than absent (P interaction, .006), and risk of wheezing was increased when maternal GSTM1 was present (P interaction, .04). Although acetaminophen use in infancy was associated with an increased risk of atopy, child antioxidant genotype did not modify associations between infant acetaminophen use and asthma phenotypes. However, the increased risk of asthma and wheezing associated with late gestation acetaminophen exposure in the presence of maternal GSTM1 was further enhanced when GSTM1 was also present in the child. CONCLUSION: Maternal antioxidant gene polymorphisms may modify the relation between prenatal acetaminophen exposure and childhood asthma, strengthening evidence for a causal association. In contrast, relations between infant acetaminophen use and asthma and atopy were not modified by child genotype and may be confounded by pre-existing wheeze or allergy.
Authors: Richard Beasley; Tadd Clayton; Julian Crane; Erika von Mutius; Christopher K W Lai; Stephen Montefort; Alistair Stewart Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: S O Shaheen; R B Newson; A J Henderson; J E Headley; F D Stratton; R W Jones; D P Strachan Journal: Clin Exp Allergy Date: 2005-01 Impact factor: 5.018
Authors: Matthew J Rose-Zerilli; Sheila J Barton; A John Henderson; Seif O Shaheen; John W Holloway Journal: Clin Chem Date: 2009-07-09 Impact factor: 8.327
Authors: Tirumalai Rangasamy; Jia Guo; Wayne A Mitzner; Jessica Roman; Anju Singh; Allison D Fryer; Masayuki Yamamoto; Thomas W Kensler; Rubin M Tuder; Steve N Georas; Shyam Biswal Journal: J Exp Med Date: 2005-07-04 Impact factor: 14.307
Authors: Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2015-08 Impact factor: 2.089
Authors: S Hasan Arshad; Wilfried Karmaus; Abid Raza; Ramesh J Kurukulaaratchy; Sharon M Matthews; John W Holloway; Alireza Sadeghnejad; Hongmei Zhang; Graham Roberts; Susan L Ewart Journal: J Allergy Clin Immunol Date: 2012-05-18 Impact factor: 10.793
Authors: Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott Journal: Inflammopharmacology Date: 2013-05-30 Impact factor: 4.473